Therefore, indicators such as microsatellite instability (MSI), PD-L1, and tumor mutational burden (TMB) were approved by the FDA as predictive markers in cancer patients and used before treatment to predict patients’ responses to specific treatments [118]. Here, CD274 is linked to neoplasm.